DDInter1553 DDInter1376
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Quetiapine {u} (Compound) resembles {v} (Compound) Trazodone
Quetiapine {u} (Compound) binds {v} (Gene) DRD5
Quetiapine {u} (Compound) upregulates {v} (Gene) SLC11A2
Quetiapine {u} (Compound) palliates {v} (Disease) autistic disorder
Quetiapine {u} (Compound) downregulates {v} (Gene) TM9SF2
Quetiapine {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Quetiapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Quetiapine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Quetiapine (Compound) resembles Trazodone (Compound)
Quetiapine (Compound) binds DRD5 (Gene)
Quetiapine (Compound) upregulates SLC11A2 (Gene)
Quetiapine (Compound) palliates autistic disorder (Disease)
Quetiapine (Compound) downregulates TM9SF2 (Gene)
Quetiapine (Compound) causes Salivary hypersecretion (Side Effect)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Quetiapine may lead to a major life threatening interaction when taken with Clarithromycin